Skip to Content

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

In this MEDtalk Dr. Jeff Sharman from Hematology Research for U.S. Oncology presents the six-year follow-up data from the Elevate-TN study. The study explores the comparative effectiveness and safety profiles of acalabrutinib with or without obinutuzumab against standard chemo-immunotherapy in the frontline treatment of Chronic Lymphocytic Leukemia (CLL), including the impact of adding obinutuzumab on progression-free survival and its implications for specific molecular subgroups.

Jeff P. Sharman

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top